bit.bio

bit.bio combines the concepts of cell programming and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines.

This is possible with our precision human cellular reprogramming technology opti-ox™ – a gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale.

MEA to probe ALS phenotypes in neuronal disease models

Consistent, functional lower motor neurons from iPSCs

Application note: Developing next-gen in vitro Huntington’s disease assays

Infographic: Differentiating iPSCs – Which approach works best?

Product hub: A reproducible and scalable Huntington’s disease human cell model

A Molecular Portrait of ALS and FTD

Right model, right complexity: using in vitro human disease cell models in drug discovery

Targeting tau – chasing a treatment for Alzheimer’s

Drug Target Review Neuroscience ebook 2022

Transcriptional reprogramming rescues vascular fate of misidentified pluripotent cell‑derived epithelial cells

Drug Target Review Stem Cells ebook 2021

bit.bio raises $103 million in first close of Series B financing

Exploring the critical roles of astrocytes in health and disease

Improving Huntington’s disease drug discovery with new reproducible disease models